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Background: Opioids are the cornerstone of treatment for moderate to severe pain, but chronic use leads to
maladaptations that include: tolerance, dependence and opioid-induced hyperalgesia (OIH). These responses limit the
utility of opioids, as well as our ability to control chronic pain. Despite decades of research, we have no therapies or
proven strategies to overcome this problem. However, murine haplotype based computational genetic mapping and a
SNP data base generated from analysis of whole-genome sequence data (whole-genome HBCGM), provides a
hypothesis-free method for discovering novel genes affecting opioid maladaptive responses.
Results: Whole genome-HBCGM was used to analyze phenotypic data on morphine-induced tolerance, dependence and
hyperalgesia obtained from 23 inbred strains. The robustness of the genetic mapping results was analyzed using strain
subsets. In addition, the results of analyzing all of the opioid-related traits together were examined. To characterize the
functional role of the leading candidate gene, we analyzed transgenic animals, mRNA and protein expression in
behaviorally divergent mouse strains, and immunohistochemistry in spinal cord tissue. Our mapping procedure identified
the allelic pattern within the netrin-1 receptor gene (Dcc) as most robustly associated with OIH, and it was also strongly
associated with the combination of the other maladaptive opioid traits analyzed. Adult mice heterozygous for the Dcc
gene had significantly less tendency to develop OIH, become tolerant or show evidence of dependence after chronic
exposure to morphine. The difference in opiate responses was shown not to be due to basal or morphine-stimulated
differences in the level of Dcc expression in spinal cord tissue, and was not associated with nociceptive neurochemical
or anatomical alterations in the spinal cord or dorsal root ganglia in adult animals.
Conclusions: Whole-genome HBCGM is a powerful tool for identifying genes affecting biomedical traits such as opioid
maladaptations. We demonstrate that Dcc affects tolerance, dependence and OIH after chronic opioid exposure, though
not through simple differences in expression in the adult spinal cord.
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Opioids are the drugs that are most commonly used for
the treatment of chronic pain. Unfortunately, maladap-
tive responses to opioids (tolerance, dependence and
OIH (opioid-induced hyperalgesia)) have greatly limited
their clinical utility [1,2]. As examples, the gradual loss* Correspondence: djclark@stanford.edu
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unless otherwise stated.of analgesic effect, worsening pain despite dosage in-
creases, and greatly exaggerated postoperative pain have
all been attributed to OIH [3-5]. Despite decades of
study, we have no specific therapies that can limit or
overcome the problems associated with chronic opioid
use. The lack of new approaches results from our limited
understanding of the mechanisms mediating the mal-
adaptive responses.
Genetic analysis offers a hypothesis-free approach that
could be used to discover the mechanisms mediating mal-
adaptive responses to opiates, and this information couldtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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differences among human populations have been shown to
explain a substantial fraction of the variance in clinically
relevant responses to opioids [6,7]. We expect genetic ap-
proaches in mice to also be informative, since there are very
large differences in the response of inbred strains to opiates,
including the development of opioid analgesia, tolerance,
dependence and hyperalgesia [8-14]. In fact, HBCGM,
which used SNP databases generated from limited se-
quence information, has identified several involved genes
including those coding for β2-adrenergic and 5-HT3 recep-
tors that affect opiate responses, and these findings were
translated to humans [8,15].
Mouse geneticists have classically used one of two ap-
proaches to analyze a murine genetic model. The first
approach is to conduct linkage (quantitative trait loci,
QTL) studies on mice derived from the interbreeding
two or more strains of mice. The identification of the
Gnao1 as a regulator of opioid physical dependence pro-
vides an important successful example for pain research
[16]. The recombinant inbred strains produced by the
Collaborative Cross have enhanced the power of this ap-
proach [17,18], and sophisticated data analysis tools are
now available [19]. As an alternative approach, HBCGM
can be used to conduct a genetic association study,
which correlates phenotypic responses with the patterns
of genetic variation present in a panel of 10 or more in-
bred strains [20]. The pattern of genetic variation is rep-
resented by haplotypes, which were constructed from
analysis of sequence data obtained from a large number
of inbred strains. This approach has identified several
genes involved in opioid maladaptive responses [12-14].
However, the lack of genome-wide sequence information
for an adequate numbers of inbred mouse strains has
previously limited the power of this technique, as have
limitations in the tools that are required to analyze the
large amount of sequence information. To overcome
these limitations, we have developed a HBCGM method
that uses a whole-genome SNP database that was gener-
ated by analysis of whole genome sequence data for 25
inbred strainsa. Here, we use this new tool to address
the public health problems associated with chronic opi-




The phenotypic data for opioid responses including anal-
gesia, tolerance, dependence and OIH was collected for 23
inbred strains of mice. Subsets of this data were used in
previous mapping efforts [8,13,14]. The behavior response
of principal interest in these studies was OIH; a mechanical
stimulus was used to characterize changes in nocicep-
tive thresholds at baseline and after chronic morphinetreatment (Figure 1). The percent reduction of mechan-
ical nociceptive thresholds after chronic opioid treat-
ment varied approximately 7-fold across the 23 strains
analyzed. Of note, there was not a significant correlation
between baseline mechanical threshold and the degree
of OIH observed after chronic morphine treatment (P >
0.05). Additional file 1: Figure S1 provides data for other
chronic opioid adaptive traits analyzed here, including:
hindpaw OIH measured using Hargreave’s thermal test-
ing, OIH measured using tail-flick thermal testing, anal-
gesic tolerance and physical dependence.
Although we focus on identifying genetic factors affecting
OIH, we previously noted (using data obtained from a
smaller number of strains) that the strain dependencies of
OIH, tolerance and physical dependence were correlated
[13]. Furthermore, the genes identified by analysis of one
opioid adaptive trait were found to affect other adaptive
traits when subsequently tested using pharmacologic agents
and transgenic animals [8,12,13]. We therefore analyzed the
correlations between the opioid adaptive traits, and found
moderate levels of correlation between the index trait
(mechanical OIH) and several opioid adaptive phenotypes
(Table 1). After correction for false discovery, however, only
the correlation between mechanical and thermal OIH
remained significant. Strains displaying more OIH assessed
using a mechanical stimulus tended to show morphine-
induced hyperalgesia to thermal stimuli as well. Moreover,
stains developing more hyperalgesia also tended to show
more tolerance and physical dependence on morphine.
These correlations are consistent with the hypothesis that
some of the same genetic variants affect diverse opioid
adaptive traits.
HBCGM results
Whole-genome HBCGM was used to analyze the opioid-
related traits. We focused on mechanical OIH as the trait
of primary interest, and examined the 15 genes whose hap-
lotypic pattern were most strongly associated with this re-
sponse (Figure 2). The 7 genes that were most strongly
associated with this phenotype had haplotype blocks that
partitioned the strains in an identical fashion, and therefore
generated the same p value. None of the top 15 genes had
previously been associated with OIH, as determined by a
search of the PubMed database (using the gene name and
“opioid-induced hyperalgesia” or “opioid” or “morphine.”)
Although these 15 genes all had highly significant statistical
correlations with mechanical OIH, it was difficult to deter-
mine which was most likely to be a causative genetic factor.
Therefore, we assessed the robustness of the mapping re-
sults as described in Methods. In brief, we determined
which of the mapped genes was most resistant (i.e. robust)
to a change in the number of strains used for the genetic
mapping. Of note, 13 of the 15 genes that were most ro-
bustly associated with OIH, were the genes that were most
Figure 1 Opioid-induced hyperalgesia in 23 strains of inbred mice. For each strain, mice were tested for mechanical nociceptive thresholds
at baseline and after 4 days of morphine treatment. Nociceptive thresholds after morphine treatment were divided by baseline values to obtain
the fraction of baseline values. For each strain n = 8 mice. Mean values are displayed +/− S.E.M.
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sponse (Table 2). However, the robustness analysis signifi-
cantly altered the gene order. The deleted in colorectal
carcinoma (Dcc) gene was the highest ranked gene by the
robustness analysis. Studies have linked this gene to behav-
ioral effects of acute and repeated exposure to stimulant
drugs of abuse, cognitive flexibility, learning and memory,
and movement disorders [21-25].
The Dcc gene is large and extends over 1.09 MB of
chromosome 18. The highly correlated haplotype block
is near the 5’ end of the first intron. The Dcc gene en-
codes a receptor for the axonal guidance cue netrin-1,
which is best described for its role in the organization of
neuronal connectivity during development, but it has
also been shown to play a role in behavioral and synaptic
plasticity in the adult brain [21,25-27]. DCC-mediated
netrin-1 signaling is also implicated in cell migration,
cell death, and angiogenesis [19,26-29]. Two SNPs in
this gene induce amino acid changes. Further analysis
revealed that the variation pattern of these two amino
acid changing SNPs divided the 23 strains into 3 groups
with low (<0.5), low and high (>0.5) fractional changes
in baseline mechanical nociceptive thresholds after ad-
ministration of morphine (Additional file 2: Figure S2).
All three strains with the A713V amino acid substitution








OIH Mech 1 0.46* 0.58† −0.50* −0.21
OIH TF 1 0.43* −0.18 0.24
OIH Therm 1 −0.38 0.11
Tolerance 1 0.41*
Dependence 1
Strain-specific trait data related to the chronic administration of morphine was
subjected to Pearson correlation analysis. The resulting correlation coefficients
are displayed. P values were adjusted using the Benjamini-Hochberg method
to control for false-discovery rate [56]. †: adjusted P value < 0.05 *: raw
p value < 0.05.thermal and mechanical stimuli, and showed little devel-
opment of tolerance as well.
To identify genes that could potentially affect other
opioid adaptive traits, we also analyzed the number of
times that a gene had a haplotype that was associated
with any one of the opioid-response traits analyzed; this
analysis also evaluated the strength of the association.
Of the associated genes, Dcc was the gene that was most
strongly associated with this group of opioid adaptive
phenotypes (Table 3). Overall, five genes appeared in the
top 15 genes identified using both the robustness and
combinatorial analysis: Dcc, Rora, Tcf4, Ctif and Lrch1.Altered Dcc expression affects opioid adaptations but not
nociceptive neurochemistry
Given the genetic mapping results, we compared the re-
sponses of mice that were heterozygous for the Dcc gene
(on a C57BL/6 background) with those of their wild type
(C57BL/6 J) littermates after chronic morphine treat-
ment. Adult heterozygous Dcc mice were used because
homozygous Dcc knockout mice die within a few hours
of birth [30]. To determine whether adult Dcc heterozy-
gous mice have reduced DCC protein levels we con-
ducted immunoblot analysis of spinal cord homogenates
and found that the Dcc heterozygous mice had ~50%
lower DCC protein levels than wild-type littermates
(Figure 3).
Despite the difference in DCC protein expression in the
spinal cord, Dcc heterozygous and wild type mice did not
differ in their basal (prior to morphine treatment) nocicep-
tive responses to thermal and mechanical stimuli, nor in
the extent of opioid analgesia observed after acute adminis-
tration of morphine to drug naïve mice (Figure 4). In con-
trast, wild-type mice displayed markedly reduced threshold
levels of mechanical hypersensitivity after chronic opioid
treatment (i.e. OIH), while Dcc heterozygous mice did not
develop OIH. In addition, Dcc heterozygous mice had
substantially reduced tolerance to morphine after several
days of treatment and developed moderately less physical


















Genes mapped to the trait of mechanical OIH were ranked after subjecting the
data to the robustness scoring procedure described in Methods. Higher scores
indicate more robust mapping results.
Figure 2 Whole-genome computational genetic mapping. The strain-specific mechanical OIH data was used for whole genome halplotypic
mapping. The top panel provides the input data for the 23 strains used. The bottom panel provides the name of the genes to which the mapped
haplotype blocks belong, the p-value for association of the block with the trait data, the maximum genetic effect attributable to the mapped
block, and the color-coded haplotypes for each of the 23 strains. The three highlighted genes contain SNPs predicted to change amino acid
sequence. In addition, chromosomal location of the mapped blocks is provided.
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(Figure 4).
To begin to discern the mechanisms underlying this
differential response to chronic morphine in Dcc hetero-
zygous mice, we examined the structural and neuro-
chemical architecture of the dorsal horns of the spinal
cords and of dorsal root ganglia (DRG) of wild-type and
Dcc heterozygous mice. We analyzed the spinal cords
and DRG for peptidergic (CGRP, SP) nerve terminals
projecting to lamina I and outer lamina II, as well as
non-peptidergic (IB4) nerve terminals projecting to the
dorsal border of inner lamina II; and for the levels of
DRG expression of selected markers. The normal archi-
tecture of these sensory endings in the dorsal spinal
cords is preserved in the Dcc heterozygous mice, and the
expression of the DRG markers in Dcc heterozygous
mice is also unchanged (Figure 5). Thus, the changes in
opioid responses observed in Dcc heterozygous mice do
not appear to be caused by a gross alteration in spinal
cord or DRG architecture.
Treatment with morphine does not change Dcc (gene and
protein) expression in spinal cord tissue
Neuroplastic changes within the spinal cord have been
associated with the development of OIH and opioid tol-
erance, and many genes undergo changes in spinal cord
gene expression after chronic morphine exposure [31].
Table 3 The integrated ranking of genes associated with

















The genes most strongly associated with the five opioid adaptive phenotypes
under study considered together are listed in the table. These traits include:
mechanical OIH (Mech OIH), OIH measured using tail flick data (TF OIH), OIH
measured using paw withdrawal testing (Therm OIH), morphine tolerance
(Tolerance) and physical dependence (Dependence). Higher scores indicate
stronger combined associations with the group of five traits.
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served to be altered after repeated exposure to amphet-
amines [32]. Therefore, we hypothesized that morphine
alters Dcc expression in mouse spinal cord tissue after
repeated exposure. However, the levels of Dcc expressionFigure 3 Spinal cord protein levels of DCC in wild type and
heterozygous mice. Lumbar spinal cord tissue from wild type and
heterozygous Dcc mice were analyzed using Western analysis. The
quantification of the DCC specific band in the immunoblots is
shown. For these experiments n = 5 mice per genotype. Data are
displayed as mean values +/− S.E.M., ***p < 0.001.in the spinal cord of C57BL/6 J mice (a morphine adap-
tive strain) and in a very adaptation-resistant strain
(129S1) were unchanged after morphine treatment mea-
sured at both the mRNA and protein levels (Figure 6).
In addition, the DCC protein levels in spinal cord tissue
in these two strains were indistinguishable under control
conditions.
Discussion
Our experiments were designed to help us better under-
stand the maladaptations to chronic opioid administra-
tion that limit the clinical utility of our most powerful
class of analgesics. A significant number of molecules
have been mechanistically linked to opioid maladapta-
tions including cell surface receptors, ion channels, drug
transporters and other proteins. However, very few stud-
ies have leveraged genetic techniques to discover the
genes involved in hypothesis-free fashion. One tech-
nique, HBCGM, has shown great promise in this re-
spect, but has to this time been limited by the lack of
whole genome sequence information and the availability
of the informatics required to use this information. The
present results demonstrate that robust mapping studies
can be completed using newly developed tools and rela-
tively easily obtainable whole genome sequence informa-
tion thus largely overcoming the previous limitations.
Our principal findings were, 1) that multiple candidate
genes could be identified by the whole genome mapping
of 23 strains of common inbred mice, 2) that techniques
such as combining the mapping results of related pheno-
types and re-sampling of strain information can be used
to help rank the candidate genes for in-depth structural
and functional analysis, 3) that the Dcc gene is computa-
tionally associated with several opioid maladaptations of
interest, and 4) that Dcc heterozygous mice display re-
silience to the development of opioid maladaptations.
Thus we have used a refined set of genetic mapping
tools to discover and subsequently confirm a novel gene
controlling maladaptations to chronic opioid use.
The Dcc gene was discovered as investigators searched
for causes of colorectal carcinoma [33]. This gene is de-
leted in approximately 70% of colorectal carcinomas
leading to the hypothesis that Dcc is a tumor suppressor
gene [28,34]. At the same time a seemingly very separate
type of function has been demonstrated for DCC pro-
tein, that of an axonal guidance molecule serving as a
receptor for netrin-1 [26,27]. In addition to misrouting of
axons caused by DCC deficiency, reduced levels of this
protein alter patterns of synaptic connections within the
developing CNS as well as synaptic plasticity within the
adult brain [21,23,35]. The integrity of DCC-mediated
netrin-1 signaling is required in the development of mul-
tiple central and peripheral nervous system structures in-
cluding the prefrontal cortex, visual system and spinal cord
Figure 4 The effects of chronic morphine treatment on Dcc
wild-type and heterozygous mice. In these experiments littermate
Dcc wild-type (C57BL/6 J) and Dcc heterozygous mice were tested
using the same chronic morphine paradigm used for the inbred
strain mapping experiments. Panel A: Mechanical OIH measure-
ments; Panel B: Morphine dose–response relationships before and
after chronic morphine treatment; Panel C: Physical dependence
measured using naloxone-precipitated jumping behavior. For these
experiments n = 11 mice per genotype. Data are displayed as mean
values +/− S.E.M., *p < 0.05, **p < 0.01, ***p < 0.001.
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such as failure of axons to cross the midline have been at-
tributed to DCC signaling insufficiency, even when loss of
Dcc expression and function are only partial [21,24,39]. The
Dcc gene itself codes for a single transmembrane spanning
receptor protein. It controls the guidance of axons (and
dendrites) towards sources of netrin-1, but it is also in-
volved in additional events including axon differentiation
and synaptogenesis [21,27,35,37]. Our observations of
spinal cord nociceptive fiber innervation suggest that cer-
tain basic nociceptive connections may be intact in dcc het-
erozygous mice, but we cannot rule out functionally
important spinal cord structural differences that would re-
quire more detailed study to detect.
While Dcc has not to this point been reported as a
specific gene regulating pain or opioid-related pheno-
types, the Dcc gene has received significant attention in
addiction-related research. Much of this work has cen-
tered on the development and adult plasticity of the
mesocorticolimbic dopamine system, a key neural sub-
strate of the actions of drugs of abuse [40,41]. In adult
rodents, sensitizing regimens of amphetamine lead to
up-regulation of DCC protein levels in the ventral teg-
mental area (VTA), the cell body regions of mesocorti-
colimbic dopamine neurons. Amphetamine-induced
increases in VTA DCC protein levels are prevented by
co-administration of NMDA receptor antagonists [32],
seems to lead to changes in synaptic plasticity, and is re-
quired for the development of behavioral sensitization to
stimulants [25]. Notably, adult Dcc heterozygous mice
do not develop behavioral sensitization to amphetamine
and fail to show reorganization of VTA synaptic con-
nectivity [25]. Similarly, exposing adult Dcc heterozygous
mice to morphine resulted in a reduced severity of opi-
oid maladaptations. It is possible that the reduction in
morphine-induced effects in the heterozygous mice is
the result of impaired morphine-induced spinal synaptic
plasticity especially in light of DCC’s link to the NMDA
receptor, a key structure in OIH and tolerance [3].
In our studies using adult mice we identified strong
effects of DCC on three clinically important opioid
maladaptations. Since none of these would be consid-
ered directly analogous to the stimulant-related pheno-
types studied by other investigators, DCC would not
Figure 5 Intact distribution and central projections of peptidergic and non-peptidergic nociceptors in Dcc heterozygous mice. Panel A:
Triple immunolabeling experiment showing similar distribution of CGRP-immunoreactivity, substance P-immunoreactivity, and binding of isolectin
B4 (IB4) in dorsal root ganglion sections from Dcc wildtype and heterozygous littermates. Panel B: Triple immunolabeling experiment indicating
that in the spinal cord dorsal horn the typical laminar organization of central terminals of peptidergic (CGRP- and substance P-expressing) and
non-peptidergic (IB4-binding) nociceptors is intact in Dcc heterozygous mice, compared to wildtype littermates.
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fects of opioids based on the existing stimulant drug re-
sponse data alone. Rather, the genetic analysis formed
the basis for our hypotheses. Distinct from the results
obtained using stimulant drugs, we failed to identify
morphine-induced effects on Dcc expression either at
the mRNA or protein levels in spinal cord tissue, a
major neuronal relay station involved in opioid toler-
ance and opioid-induced hyperalgesia [3,42]. However,
such drug-induced changes may not be necessary if
functionally important but as yet unidentified differ-
ences in CNS structure between the strains of mice exist
even before drug exposure, or if different Dcc alleles
cause differences in function rather than expression.
The latter possibility might be caused by one of the
identified SNP variants predicted to change amino acid
sequence. In this respect the A713V variant is of great
interest as it appears to be associated with a high versus
low likelihood of developing either OIH or opioidanalgesic tolerance. Though the alanine to valine substi-
tution involves two similar hydrophobic amino acids,
similar changes have been shown to cause profound
changes in glycine receptor function [43]. Importantly,
baseline nociceptive thresholds and analgesic potency of
morphine were unaltered in heterozygous mice suggest-
ing that reduced DCC availability may still be sufficient
to support the basic development and maintenance of
primary pain-related circuitry, but that the ability of
adult animals to adapt to sustained morphine adminis-
tration is reduced. For example, changes in the forma-
tion of synapses within the spinal cord dorsal horn or
alterations in the density of descending modulatory fi-
bers from the medulla, another CNS center strongly as-
sociated with opioid adaptations [44,45], may modulate
the Dcc genetic effects. Alternatively, DCC is known to
be involved in formation of the locus coeruleus [46], a
major brain center linked to descending noradrenergic
control of spinal pain signaling and opioid tolerance
Figure 6 Expression of Dcc in spinal cord tissue after chronic
morphine treatment in C57/6 J and 129S1 mice. Panel A: The
mRNA levels of Dcc were unchanged after chronic morphine
treatment in both C57/6 J and 129S1 mice. Values are displayed as
the mean ± SEM, n = 6. ns, no significant difference. Panel B: Western
blot assay demonstrated that there was no significant difference in
baseline levels of DCC in spinal cord tissue from C57/6 J and 129S1
mice. Panel C: The spinal cord protein levels of DCC were
unchanged after chronic morphine treatment in both C57/6 J and
129S1 mice. Values are displayed as the mean ± S.E.M., n = 4. ns, no
significant difference. Veh = vehicle, Mor =morphine treatment.
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be designed.
Conclusions
In this report we provide one of the first examples of the
use of whole-genome murine HBCGM to successfully map
a drug-related behavioral trait. We have demonstrated theutility of testing the robustness of the mapping results by
the re-analysis of strain subgroups and by combining the
results of mapping of related phenotypes. While we focused
on the function of our top ranked gene, Dcc, many add-
itional gene variants are likely important. Given the design
of the tools we have developed, further increasing their
power by sequencing additional strains and measuring add-
itional phenotypes of interest should be straightforward.
Though the collection of phenotypic data from large num-
bers of inbred strains of mice can be an arduous process,
especially for complex behavioral paradigms, such efforts
may pay large dividends in the form of novel hypotheses
generated from whole genome analysis.
Methods
Animal care and use
All experimental protocols were reviewed and approved
by Veterans Affairs Palo Alto Healthcare System Insti-
tutional Animal Care and Use Committee prior to be-
ginning the work. All mice used in this series of
experiments were kept under pathogen-free conditions,
4 mice per cage with a 12 h light/dark cycle and an am-
bient temperature of 22 ± 1°C. Food and water were
available ad libitum.
All mice used for the mapping experiments were
male and were obtained from The Jackson Laboratory
(Bar Harbor, MA) at 11–12 weeks of age, and were kept
in our facility a minimum of 1 week prior to use in ex-
periments. The identity of each of the inbred strains
used and the Jackson Laboratories catalog number are
listed in Additional file 3: Table S1. Mice heterozygous
for the deleted in colorectal carcinoma (Dcc) gene and
wild-type littermates were bred from animals initially
supplied by S. Ackerman (The Jackson Laboratory)
[48]. The original Dcctm1Wbg mice [30] have been
crossed back to C57BL6/J for a minimum of 36 genera-
tions. Cryopreserved material of this mouse strain is




After baseline nociceptive testing, morphine (Sigma
Chemical Co.) was administered to mice subcutane-
ously (s.c.) 20 mg/kg twice per day on days 1–3 and
40 mg/kg twice per day on day 4 in 50–100 μl volumes
of 0.9% NaCl similar to our previous protocols for gen-
erating opioid-induced hyperalgesia [12-14].
Behavioral testing
Thermal withdrawal latency (Hargreaves’ testing) - Re-
sponse latencies to noxious thermal stimulation of the
plantar surface of the hindpaw were measured as de-
scribed previously [13]. Briefly, mice were placed on a
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cylinders. After acclimation, focused light was focused
on the plantar surface of the hind paw between the foot
pads. The time to withdrawal of the foot was measured
to 0.1 sec, and a 20-second cutoff was used to prevent
tissue damage. The light beam intensity was adjusted to
provide an approximate 10 second baseline latency for the
C57BL/6 index strain prior to morphine treatment and the
same light intensity was used for all subsequent experi-
ments for all strains. Two measurements were made per
animal per test session. Latencies were measured at base-
line, and again 18 hours after the final dose of morphine
when thermal and mechanical OIH were maximal. Our
index of thermal OIH was calculated as the percentage de-
crease in baseline thermal withdrawal latency resulting
from chronic morphine administration.
Mechanical withdrawal thresholds - Mechanical with-
drawal testing was performed as described previously
[14]. Briefly, mechanical nociceptive thresholds were
assayed using nylon von Frey filaments according to
the “up-down” algorithm described by Chaplan et al.
[49]. In these experiments mice were placed on wire
mesh platforms in plastic cylinders. After acclimation,
fibers of sequentially increasing stiffness were applied
to the plantar surface of a hind paw according to the
up-down paradigm. Testing proceeded in this manner
until 4 fibers had been applied after the first one caus-
ing a withdrawal response allowing the estimation of
the mechanical withdrawal threshold using curve fitting
of the response data [50]. Our index of mechanical
OIH was calculated as the percentage decrease in base-
line mechanical nociceptive threshold resulting from
chronic morphine administration.Morphine dose–response
Cumulative morphine dose–response curves were con-
structed as described previously [11,12]. Briefly, the
thermal withdrawal latencies of gently restrained mice
were measured using a tail-flick apparatus (Columbus
Instruments, Columbus, OH) with 0.1 second precision.
Two measurements were made per mouse. The lamp
intensity was the same for all strains. For the assess-
ment of morphine analgesic tolerance, these dose–re-
sponse experiments were made on morphine naïve
mice and again 18 hours after the final dose of mor-
phine given as part of the chronic morphine adminis-
tration protocol. The cumulative doses of morphine
used were 0,1,2,4,8,16 and 32 mg/kg s.c.. Tail flick la-
tency was determined 25 minutes after morphine ad-
ministration as demonstrated previously to be the time
of peak morphine effect. The parameter %MPE (percent
maximal possible effect) was determined according to
the following formula:%MPE ¼ ðmeasured latency–baseline latency½ Þ
= cutoff latency–baseline latencyð Þ X 100
Physical dependence
Morphine physical dependence was measured using
methods previously reported by our laboratory [11,12].
Mice were treated with morphine for 4 days according
to the standard morphine administration protocol for
use in this paradigm. Dependence was assessed 18 hours
after the final dose of morphine was given. To precipi-
tate withdrawal, naloxone (Sigma Chemical Co.) 10 mg/
kg was injected s.c. in 50 μl 0.9% NaCl. After naloxone
administration, mice were placed in the same clear cyl-
inders used for the mechanical nociception assays. The
number of jumps made during the following 15 minutes
was counted.
Genetic mapping
Whole-genome computational genetic mapping- Whole-
genome variation information was obtained from public
data bases (10 inbred strains) [51] and through next-
generation sequencing of commercially obtained DNA
(The Jackson Laboratory) for the remaining 13 strains
(Beijing Genomics Institute, BGI) [52]. Haplotype-based
computational genetic mapping (HBCGM) was conducted
as described previously [53], and used to identify those
genomic regions whose genetic variation pattern was cor-
related with input phenotypic values for the 23 inbred
strains utilized in these studies.
Computational genetic mapping testing for robustness-
To assess the robustness of HBCGM using different subsets
of input strain data, we developed software that could auto-
matically perform a re-sampling analysis. For each iteration,
a number (3, 4, 5 or 6) was randomly selected to determine
the number of strains that would be randomly excluded
from the 23 total available strains. This number of ran-
domly selected strains was then excluded from mapping
analysis. The haplotypes identified with p < 0.01 were tabu-
lated. This process was repeated 100 times. If a re-sampled
strain panel was identical to one that had already been re-
sampled, this iteration was disregarded, and another subset
was randomly chosen using the same procedure. To meas-
ure the overall association of a gene with the phenotype
among the 100 random re-sampled subsets, we defined a




‐ log10 pið Þ , where pi was the resulting p value
for that gene in the ith re-sampled experiment (if the p
value was bigger than the cutoff and therefore censored in
the result, pi was set to 0.01, i.e. the cutoff). Using this ap-
proach, genes with larger scores have stronger overall cor-
relation. The genes were then ranked by their calculated
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of the top 50 genes.
Integration of computational genetic mapping results
across related traits- To measure the overall association
of a gene with multiple related traits, HBCGM was first
applied to evaluate each trait. The number of times any
region corresponding to this gene was associated with a
trait of interested (p < 0.01) was counted. To take the
strength of association into account, a score similar to




‐ log10 pið Þ, where i runs through all traits of
interest and pi was defined as previously described. In
general, genes with multiple highly significant associa-
tions have high scores and therefore are of higher
interest.
Protein isolation and analysis
Mice were first euthanized by carbon dioxide asphyxi-
ation and spinal cord tissue was harvested by extrusion.
Lumbar spinal cord segments were dissected on a chilled
surface. The lumbar area of the spinal cord was readily
identified by its enlargement, and the area spanning the
approximate L3 through S1 segments was harvested.
Dissected tissue was then quick-frozen in liquid nitrogen
and stored at −80°C until required for analysis. Spinal
cords were dissolved at 4°C in RIPA buffer (50 mM
Tris–HCl, pH 8.0, 150 mM sodium chloride, 1.0% NP-
40, 0.5% sodium deoxycholate, and 0.1% sodium dodecyl
sulfate) in the presence of protease inhibitor cocktail
(Roche, Mannheim, Germany). Equal amounts of protein
(20 μg) were loaded for SDS-PAGE (10% Tris–HCl
acrylamide gel) and electrotransferred onto a polyvinyli-
dene difluorided membranes as described previously
[54]. Blots were probed with the primary antibody of
DCC monocolonal antibody (1:1000, BD Pharmingen,
San Diego, CA) at 4°C overnight. β-actin (Sigma Chem-
ical, St. Louis, MO) was used as an internal control. This
antibody produces a single band at approximately
~185 kDa on Western blots consistent with the pre-
dicted weight of DCC. The specificity of this antibody
has been validated previously using embryonic tissues
from Dcc knockout and Dcc wild type embryos [55]. The
band intensity was quantified using National Institutes
of Health image J analysis software (version 1.44, Be-
thesda, MD).
RNA isolation and analysis
The spinal cord samples were dissected and stored as de-
scribed above. For RNA and real-time quantitative PCR,
total RNA was isolated from spinal cord using the RNeasy
Mini Kit (Qiagen, Valencia, CA) according to the manufac-
turer's instructions. The purity and concentration weredetermined spectrophotometrically. Reverse transcription
was accomplished using a First Strand complementary
DNA Synthesis Kit (Invitrogen, Carlsbad, CA). Real-time
PCR was performed in an ABI prism 7900HT system (Ap-
plied Biosystems, Foster City, CA). All PCR experiments
were performed using the SYBR Green I master kit (Ap-
plied Biosystems). The Dcc primers were purchased from
SABiosciences (Catalog number: PPM03679F, SABios-
ciences, Valencia, CA). The sequences for the GAPDH
primers were (forward primer) 5-CTGGAGAAACCTG
CCAAGTATGATG-3 and (reverse primer) 5-GAGACA
ACCTGGTCCTCAGTGTAGC-3. Quantification was ac-
complished according to the standard curve method. In
order to achieve the same PCR efficiency for each analyte,
1:10 serial dilutions of cDNA were used to construct stand-
ard curves for Dcc and GAPDH. The R2 values for the
standard curves for each analyte approached 1.0, suggesting
the same amplification efficiency in the PCR reactions
under these conditions. Melting curves were performed to
document single product formation and agarose electro-
phoresis confirmed product size. As negative controls,
RNA samples that were not reverse transcribed were run.
Data were normalized to GAPDH mRNA expression.
Immunohistochemistry
Mice were deeply anesthetized with 100 mg/kg sodium
pentobarbital and perfused transcardially with 10 mL of
0.1 M PBS followed by 30 mL of 3.7% formaldehyde so-
lution (Sigma-Aldrich). The lumbar dorsal root ganglia
(DRG) and spinal cord were dissected, post-fixed in the
same fixative for 4 hrs, and cryoprotected overnight in
30% sucrose in 0.1 M PBS. Spinal cords were sectioned
on a cryostat at 40 μm and processed as free-floating
sections. DRG were sectioned at 20 μm and processed
on slides (Superfrost, Fisher Scientific). Tissue was first
incubated for at least 1 hr in 0.1 M PBS with 0.3% Tri-
ton X-100 (Sigma-Aldrich) plus 5% normal donkey
serum (NDS, EMD-Millipore) blocking solution. Pri-
mary antibodies were diluted in 0.1 M PBS with 0.3%
Triton X-100 plus 5% NDS. Secondary antibodies were
diluted in 0.1 M PBS with 0.3% Triton X-100 plus 1%
NDS. Tissue was incubated overnight at 4°C in primary
antibody, washed with 0.1 M PBS with 0.3% Triton X-
100 plus 1% NDS, and then incubated for 2 hrs in sec-
ondary antibody at RT. Tissue was then washed with
0.1 M PB, and coverslipped with Fluoromount-G
mounting medium (Southern Biotech). Images were ac-
quired with a Leica TCS SPE confocal microscope. We
used the following antibodies and reagents: sheep anti-
CGRP (Abcam, 1:1,500); IB4 (Sigma-Aldrich, 1:1,000);
guinea pig anti-Substance P (gift from J. Maggio,
1:10,000), Alexa Fluor 488 donkey anti-sheep; Alexa
Fluor 555 streptavidin, Alexa Fluor 647 donkey anti-
guinea pig.
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All data are displayed as the means +/− SEM unless
otherwise noted. Dose–response data was fitted using a
sigmoidal function with variable slope (Prism 5, Graph-
Pad Software, San Diego, CA). Where more than 2
groups were employed, ANOVA analysis was applied
with the Tukey test applied post-hoc. Pair-wise correla-
tions and the corresponding p values were calculated
using R (www.r-project.org). The p values were then ad-
justed using the Benjamini-Hochberg method to control
for false-discovery rate [56].
Endnote
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Additional file 1: Figure S1. Additional opioid adaptive traits in 23
strains of inbred mice. Panel A: Opioid-induced hyperalgesia (OIH)
measured using thermal paw withdrawal (Hargreaves’) testing; Panel B:
OIH measured using the tail flick assay; Panel C: Physical dependence
measured using naloxone-precipitated jumping behavior; Panel D:
Morphine tolerance measured as the shift in ED50 after 4 days of
morphine treatment. For panels A and B, nociceptive thresholds after
morphine treatment were divided by baseline values to obtain the
fraction of baseline values. For each trait the mean value is
displayed +/− S.E.M., n = 8 mice per strain.
Additional file 2: Figure S2. The genomic positions as well as the
amino acid residues that the SNPs change are shown in the first two
rows. For each strain, possessing the reference (C57/6J) allele is coded as
blue. Yellow signifies the alternative allele. Based on the resulting pattern,
the 23 strains were divided into 3 groups: the strains in the first two
groups have predominantly high fractional changes in mechanical
nociceptive thresholds after morphine exposure (>0.5), while the strains
in the 3rd group all have low fractional changes after morphine
exposure (<0.5).
Additional file 3: Table S1. Strain names and Jackson Laboratories
catalog numbers for experimental mice.
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